XBIState Street SPDR S&P Biotech ETF

$10.7B

net assets, all share classes

0.35%

yearly cost, from the prospectus

161

positions on file

+91.7%

last 12 months

+24.1%

a year, over 3 years

+3.3%

a year, over 5 years

State Street Global AdvisorsCash and short-term

5.9%

Apogee Therapeutics Inc

1.5%

MRNA Moderna

1.4%0.57% of MRNA

TWST Twist Bioscience Corporation

1.4%2.42% of TWST

ORKA Oruka Therapeutics, Inc.

1.4%2.44% of ORKA

KYMR Kymera Therapeutics, Inc.

1.4%1.53% of KYMR

VKTX Viking Therapeutics, Inc.

1.3%2.84% of VKTX

PRAX Praxis Precision Medicines, Inc.

1.3%1.48% of PRAX

ERAS Erasca, Inc.

1.3%2.19% of ERAS

RVMD Revolution Medicines, Inc.

1.2%0.32% of RVMD

1. NVAXNovavax, Inc.0.7% of the fund4.5% of the company
2. SLSSELLAS Life Sciences Group, Inc.1.2% of the fund4.3% of the company
3. NTLAIntellia Therapeutics, Inc.0.9% of the fund4.2% of the company
4. ALTAltimmune, Inc.0.2% of the fund4.2% of the company
5. SRPTSarepta Therapeutics, Inc.0.7% of the fund4.2% of the company
6. OCGNOcugen, Inc.0.2% of the fund4.1% of the company

The closest is IBB (iShares Biotechnology ETF): 40%of the two funds’ stock holdings are the same.

1. IBBiShares Biotechnology ETF0.44% a year40% in common
2. IWOiShares Russell 2000 Growth ETF0.24% a year13% in common
3. VHTVanguard Health Care ETF0.09% a year13% in common
4. VBKVanguard Small-Cap Growth ETF0.05% a year10% in common
5. IWMiShares Russell 2000 ETF0.19% a year8.9% in common
6. VTWOVanguard Russell 2000 ETF0.06% a year7.2% in common

XBI costs 0.35% a year. Overlap counts only the stocks we can match to a listing; bonds, cash and unmatched foreign shares are left out. Every group of near-identical funds and what each costs.